---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-292704"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2026-07-01T20:41:06+00:00"
generated_at: "2026-07-01T20:42:12.478188+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Jade Biosciences licenses monospecific antibodies from Paragon for up to $22M in milestones

## Summary
- Paragon grants exclusive worldwide license to undisclosed target antibodies for all human therapeutic areas.
- Jade pays up to $22M in development/regulatory milestones; $1.5M already paid for candidate nomination.
- Additional sublicensing fees up to ~$20.1M on commercial milestones; royalties low to mid-single-digit.
- Paragon restricted from generating monospecific antibodies targeting same target for at least 5 years.
- Jade can terminate on 60 days' notice; agreement subject to standard termination provisions.

## SEC filing metadata
- accession: 0001193125-26-292704
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2026-07-01T20:41:06+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000119312526292704/0001193125-26-292704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000119312526292704/d145208d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-292704
- JSON: https://secwatch.observer/filing/0001193125-26-292704.json
- Plain text: https://secwatch.observer/filing/0001193125-26-292704.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.